Meditrina is a technology company.
Meditrina has raised $23.0M across 2 funding rounds.
Meditrina has raised $23.0M in total across 2 funding rounds.
Meditrina has raised $23.0M in total across 2 funding rounds.
Meditrina's investors include Deerfield Management, Alumni Ventures, Anderson Angels, Bascom Ventures, DBL Partners, Family Office, Modern Venture Partners, Shangbay Capital, The Hit Forge.
Meditrina, Inc. is a medical technology company specializing in innovative devices for minimally invasive gynecology, particularly the Aveta™ System—an all-in-one hysteroscopy suite for treating intrauterine pathologies like polyps and fibroids.[2][4][5] It serves physicians and healthcare providers in office and operating room settings, addressing challenges in tissue resection, fluid management, and visualization to enable efficient, patient-centered procedures with faster recovery and fertility preservation potential.[2][5] Founded in 2016 and based in California, the company secured $13 million in equity financing in 2019 (led by ShangBay Capital and Aethan Capital) to support FDA-cleared commercialization, followed by growth funding from Deerfield in 2020; revenue remains private but estimated low (<$5M).[2][4][5] Note: A separate entity, Meditrina Technologies (founded 2021 in Virginia), develops a corporate wellness app for SMBs, but the query aligns more closely with the medtech firm's prominence.[1][6]
Meditrina, Inc. was founded in 2016 in California, focusing on advanced hysteroscopy systems for women's healthcare.[4] Csaba Truckai serves as President and CEO, leading development of proprietary platforms including an expandable working channel hysteroscope, high-speed mechanical oscillation, fluid control algorithms, and HD CMOS visualization.[2] The idea emerged from unmet needs in intrauterine pathology treatment, culminating in FDA 510(k) clearance for the Aveta™ System in May 2019.[2] Pivotal early traction came via a $13 million equity round in October 2019, led by ShangBay Capital (with William Dai joining the board) and Aethan Capital, funding US commercialization.[2] Additional growth capital from Deerfield in April 2020 marked mid-stage expansion.[4]
Meditrina rides the wave of minimally invasive gynecology and office-based procedures, driven by demands for cost-effective, patient-friendly alternatives to inpatient surgeries amid rising healthcare costs and fertility awareness.[2][3][5] Timing aligns with FDA advancements enabling faster market entry for hysteroscopy innovations, while market forces like aging populations and increasing uterine disorder prevalence (e.g., fibroids affecting millions) favor scalable systems like Aveta.[3] It influences the ecosystem by setting potential new standards in tissue resection efficiency, supporting broader medtech shifts toward integrated, physician-controlled devices that reduce procedural complexity.[2][4]
Meditrina is poised for expanded US adoption of the Aveta™ System, leveraging its FDA clearance and funding to capture share in the growing hysteroscopy market amid trends like outpatient care and AI-enhanced imaging.[2][3][5] Future shape comes from medtech consolidation, potential pipeline expansions in gynecology, and partnerships for global reach, evolving its influence toward gold-standard procedures in women's health.[2][4] As a focused innovator commercializing post-2019 clearance, it exemplifies how targeted devices tackle entrenched clinical challenges, building on its financing momentum for sustained growth.
Meditrina has raised $23.0M across 2 funding rounds. Most recently, it raised $10.0M Venture Round in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $10.0M Venture Round | Deerfield Management | |
| Oct 1, 2019 | $13.0M Venture Round | Alumni Ventures, Anderson Angels, Bascom Ventures, DBL Partners, Family Office, Modern Venture Partners, Shangbay Capital, The Hit Forge |